The role of osteoanabolic agents in the management of patients with osteoporosis

References

• Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364–376.
   PubMed Web of Science ®Google Scholar
• Kendler DL, Bauer DC, Davison KS, et al. Vertebral fractures: clinical Importance and management. Am J Med. 2016;129(2):221 e1–10.
   Web of Science ®Google Scholar
• Lewiecki EM, Ortendahl JD, Vanderpuye-Orgle J, et al. Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States. JBMR Plus. 2019;3(9):e10192.
   PubMedGoogle Scholar
• Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College Of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020;26(Suppl 1):1–46.
   PubMed Web of Science ®Google Scholar
• Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2020;105(3):587–594.
   Web of Science ®Google Scholar
• Lewiecki EM, Binkley N, Clark P, et al. Core principles for fracture prevention: North American consensus from the National Osteoporosis Foundation, Osteoporosis Canada, and Academia Nacional de Medicina de Mexico. Osteoporos Int. 2020;31(11):2073–2076.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):1–12.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Harvey NC, et al. An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines: a report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int. 2021;32(10):1951–1960.
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26(5):688–703.
   PubMed Web of Science ®Google Scholar
• Minisola S, Cipriani C, Grotta GD, et al. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2019;11:1759720X19877994.
   PubMed Web of Science ®Google Scholar
• Miller PD, Bilezikian JP, Fitzpatrick LA, et al. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Curr Med Res Opin. 2020;36(11):1861–1872.
   PubMed Web of Science ®Google Scholar
• Brent MB. Abaloparatide: a review of preclinical and clinical studies. Eur J Pharmacol. 2021;909:174409.
   PubMed Web of Science ®Google Scholar
• McClung MR. Clinical utility of anti-sclerostin antibodies. Bone. 2017;96:3–7.
   PubMed Web of Science ®Google Scholar
• Kaveh S, Hosseinifard H, Ghadimi N, et al. Efficacy and safety of romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis. Clin Rheumatol. 2020;39(11):3261–3276.
   PubMed Web of Science ®Google Scholar
• Dempster DW, Zhou H, Ruff VA, et al. Longitudinal effects of teriparatide or zoledronic acid on bone modeling- and remodeling-based formation in the SHOTZ study. J Bone Miner Res. 2018;33(4):627–633.
   PubMed Web of Science ®Google Scholar
• Dempster DW, Zhou H, Rao SD, et al. Early effects of abaloparatide on bone formation and resorption indices in postmenopausal women with osteoporosis. J Bone Miner Res. 2021;36(4):644–653.
   PubMed Web of Science ®Google Scholar
• Leder BZ, O’Dea LS, Zanchetta JR, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015;100(2):697–706.
   PubMed Web of Science ®Google Scholar
• Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–733.
   PubMed Web of Science ®Google Scholar
• Miller PD, Lewiecki EM, Krohn K, et al. Teriparatide: label changes and identifying patients for long-term use. Cleve Clin J Med. 2021;88(9):489–493.
   PubMed Web of Science ®Google Scholar
• Radius Health. TYMLOS Prescribing Information 2018 Accessed 28 March 2022 Available from: https://radiuspharm.com/wp-content/uploads/tymlos/tymlos-prescribing-information.pdf
   Google Scholar
• Radius Health. Radius announces results from the wearABLe Trial evaluating abaloparatide transdermal system in postmenopausal women with osteoporosis 2021 Accessed 28 March 2022. Available from: https://ir.radiuspharm.com/news-releases/news-release-details/radius-announces-results-wearable-trial-evaluating-abaloparatide
   Google Scholar
• Chavassieux P, Chapurlat R, Portero-Muzy N, et al. Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J Bone Miner Res. 2019;34(9):1597–1608.
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–420.
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441.
   PubMed Web of Science ®Google Scholar
• Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–1543.
   PubMed Web of Science ®Google Scholar
• Diez-Perez A, Marin F, Eriksen EF, et al. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone. 2019;120:1–8.
   PubMed Web of Science ®Google Scholar
• Leder BZ, Tsai JN, Uihlein AV, et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA Extension study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99(5):1694–1700.
   PubMed Web of Science ®Google Scholar
• Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386(9999):1147–1155.
   PubMed Web of Science ®Google Scholar
• Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103(8):2949–2957.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME Extension study. J Bone Miner Res. 2019;34(3):419–428.
   PubMed Web of Science ®Google Scholar
• Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–1427.
   PubMed Web of Science ®Google Scholar
• Brown JP, Engelke K, Keaveny TM, et al. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the active-controlled fracture study in postmenopausal women with osteoporosis at high risk (ARCH) trial. J Bone Miner Res. 2021;36(11):2139–2152.
   PubMed Web of Science ®Google Scholar
• Leder BZ, Mitlak B, Hu MY, et al. Effect of abaloparatide vs alendronate on fracture risk reduction in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2020;105(3):938–943.
   Web of Science ®Google Scholar
• Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230–240.
   PubMed Web of Science ®Google Scholar
• Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87(10):4528–4535.
   PubMed Web of Science ®Google Scholar
• Hadji P, Zanchetta JR, Russo L, et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2012;23(8):2141–2150.
   PubMed Web of Science ®Google Scholar
• Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382(9886):50–56.
   PubMed Web of Science ®Google Scholar
• Kobayakawa T, Miyazaki A, Saito M, et al. Denosumab versus romosozumab for postmenopausal osteoporosis treatment. Sci Rep. 2021;11(1):11801.
   PubMed Web of Science ®Google Scholar
• Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004;32(4):426–438.
   PubMed Web of Science ®Google Scholar
• Jolette J, Attalla B, Varela A, et al. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34). Regul Toxicol Pharmacol. 2017;86:356–365.
   PubMed Web of Science ®Google Scholar
• Gilsenan A, Harris D, Reynolds M, et al. Long-term cancer surveillance: results from the Forteo patient registry surveillance study. Osteoporos Int. 2021;32(4):645–651.
   PubMed Web of Science ®Google Scholar
• Gilsenan A, Midkiff K, Harris D, et al. Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res. 2021;36(2):244–251.
   PubMed Web of Science ®Google Scholar
• Kellier-Steele N, Casso D, Anderson A, et al. Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes. Bone. 2022;160:116394.
   PubMed Web of Science ®Google Scholar
• Radius Health. Radius announces update on TYMLOS® (abaloparatide) label. 2021 Accessed 28 March 2022. Available from: https://ir.radiuspharm.com/news-releases/news-release-details/radius-announces-update-tymlosr-abaloparatide-label
   Google Scholar
• European Medicines Agency. Refusal of the marketing authorisation for Eladynos (abaloparatide). 2017 Accessed 28 March 2022 Available from: https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-eladynos-abaloparatide_en.pdf
   Google Scholar
• Rodriguez AJ, Ernst MT, Nybo M, et al. Oral bisphosphonate use reduces cardiovascular events in a cohort of Danish patients referred for bone mineral density. J Clin Endocrinol Metab. 2020;105(10):3215–3225.
   Web of Science ®Google Scholar
• Cummings SR, McCulloch C. Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab. Osteoporos Int. 2020;31(6):1019–1021.
   PubMed Web of Science ®Google Scholar
• Turk JR, Deaton AM, Yin J, et al. Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Regul Toxicol Pharmacol. 2020;115:104697.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Kendler DL, Davison KS, et al. Western Osteoporosis Alliance clinical practice series: treat-to-target for osteoporosis. Am J Med. 2019;132(11):e771–e7.
   PubMed Web of Science ®Google Scholar
• Curtis EM, Reginster JY, Al-Daghri N, et al. Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res. 2022;34(4):695-714.
   Google Scholar
• Keaveny TM, Crittenden DB, Bolognese MA, et al. Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32(9):1956–1962.
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585–1594.
   PubMed Web of Science ®Google Scholar
• Adami S, San Martin J, Munoz-Torres M, et al. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int. 2008;19(1):87–94.
   PubMed Web of Science ®Google Scholar
• McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33(8):1397–1406.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Binkley N, Bilezikian JP. Treated osteoporosis is still osteoporosis. J Bone Miner Res. 2019;34(4):605–606.
   PubMed Web of Science ®Google Scholar
• Cosman F, Wermers RA, Recknor C, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab. 2009;94(10):3772–3780.
   PubMed Web of Science ®Google Scholar
• Minne H, Audran M, Simoes ME, et al. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin. 2008;24(11):3117–3128.
   PubMed Web of Science ®Google Scholar
• McClung MR, Bolognese MA, Brown JP, et al. Skeletal responses to romosozumab after 12 months of denosumab. JBMR Plus. 2021;5(7):e10512.
   PubMedGoogle Scholar
• Ferrari S, Libanati C, Lin CJF, et al. Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment. J Bone Miner Res. 2019;34(6):1033–1040.
   PubMed Web of Science ®Google Scholar
• Cosman F, Lewiecki EM, Ebeling PR, et al. T-score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial. J Bone Miner Res. 2020;35(7):1333–1342.
   PubMed Web of Science ®Google Scholar
• Bouxsein ML, Eastell R, Lui LY, et al. Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res. 2019;34(4):632–642.
   PubMed Web of Science ®Google Scholar
• Black DM, Bauer DC, Vittinghoff E, et al. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8(8):672–682.
   PubMed Web of Science ®Google Scholar
• Idolazzi L, Rossini M, Viapiana O, et al. Teriparatide and denosumab combination therapy and skeletal metabolism. Osteoporos Int. 2016;27(11):3301–3307.
   PubMed Web of Science ®Google Scholar
• Ebina K, Tsuboi H, Nagayama Y, et al. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine. 2021;88(5):105219.
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1):9–17.
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16(5):510–516.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Blicharski T, Goemaere S, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183–3193.
   PubMed Web of Science ®Google Scholar
• Radius Health. Radius announces positive phase 3 topline results for TYMLOS® (abaloparatide) subcutaneous injection in males with osteoporosis Accessed 28 March 2022. Available from: https://ir.radiuspharm.com/news-releases/news-release-details/radius-announces-positive-phase-3-topline-results-tymlosr
   Google Scholar
• Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–2039.
   PubMed Web of Science ®Google Scholar
• Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346–3355.
   PubMed Web of Science ®Google Scholar
• Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391–420.
   PubMed Web of Science ®Google Scholar
• Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017;5(11):908–923.
   PubMed Web of Science ®Google Scholar
• Krege JH, Lane NE, Harris JM, et al. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int. 2014;25(9):2159–2171.
   PubMed Web of Science ®Google Scholar
• McClung MR. Using osteoporosis therapies in combination. Curr Osteoporos Rep. 2017;15(4):343–352.
   PubMed Web of Science ®Google Scholar
• Kendler DL, Bone HG, Massari F, et al. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int. 2019;30(12):2437–2448.
   PubMed Web of Science ®Google Scholar
• Cosman F, Nieves JW, Zion M, et al. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res. 2009;24(6):1110–1115.
   PubMed Web of Science ®Google Scholar
• Borges JL. Accelerated fracture healing with teriparatide. Arch Endocrinol Metab. 2015;59(1):89.
   PubMed Web of Science ®Google Scholar
• Schemitsch EH, Miclau T, Karachalios T, et al. A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures. J Bone Joint Surg Am. 2020;102(8):693–702.
   PubMed Web of Science ®Google Scholar
• Balasubramanian A, Zhang J, Chen L, et al. Risk of subsequent fracture after prior fracture among older women. Osteoporos Int. 2019;30(1):79–92.
   PubMed Web of Science ®Google Scholar
• Bernhardsson M, Aspenberg P. Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models. Acta Orthop. 2018;89(6):674–677.
   PubMed Web of Science ®Google Scholar
• Lanske B, Chandler H, Pierce A, et al. Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fracture. J Orthop Res. 2019;37(4):812–820.
   PubMed Web of Science ®Google Scholar
• Feng G, Chang-Qing Z, Yi-Min C, et al. Systemic administration of sclerostin monoclonal antibody accelerates fracture healing in the femoral osteotomy model of young rats. Int Immunopharmacol. 2015;24(1):7–13.
   PubMed Web of Science ®Google Scholar
• Hamann C, Rauner M, Hohna Y, et al. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res. 2013;28(3):627–638.
   PubMed Web of Science ®Google Scholar
• Moon SW, Lee DH, Kim YC, et al. Parathyroid hormone 1-34 (teriparatide) treatment in pelvic insufficiency fractures - a report of two cases. J Bone Metab. 2012;19(2):147–151.
   PubMedGoogle Scholar
• Yoo JI, Ha YC, Ryu HJ, et al. Teriparatide treatment in elderly patients with sacral insufficiency fracture. J Clin Endocrinol Metab. 2017;102(2):560–565.
   PubMed Web of Science ®Google Scholar
• Raghavan P, Christofides E. Role of teriparatide in accelerating metatarsal stress fracture healing: a case series and review of literature. Clin Med Insights Endocrinol Diabetes. 2012;5:39–45.
   PubMedGoogle Scholar
• Kim SM, Kang KC, Kim JW, et al. Current role and application of teriparatide in fracture healing of osteoporotic patients: a systematic review. J Bone Metab. 2017;24(1):65–73.
   PubMedGoogle Scholar
• Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404–414.
   PubMed Web of Science ®Google Scholar
• Nieves JW, Cosman F, McMahon D, et al. Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial. Osteoporos Int. 2022;33(1):239–250.
   PubMed Web of Science ®Google Scholar
• Bhandari M, Schemitsch EH, Karachalios T, et al. Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture: a randomized phase-2 study. J Bone Joint Surg Am. 2020;102(16):1416–1426.
   PubMed Web of Science ®Google Scholar
• Sim IW, Borromeo GL, Tsao C, et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. J Clin Oncol. 2020;38(26):2971–2980.
   PubMed Web of Science ®Google Scholar
• Mastaglia SR, Aguilar G, Oliveri B. Teriparatide for the rapid resolution of delayed healing of atypical fractures associated with long-term bisphosphonate use. Eur J Rheumatol. 2016;3(2):87–90.
   PubMedGoogle Scholar
• Kondo N, Miyasaka D, Watanabe Y, et al. Atypical femoral fracture associated with delayed union for which the cessation of alendronate and daily administration of teriparatide contributed to fracture healing: histopathological evidence of the enhancement in bone formation parameters. Mod Rheumatol Case Rep. 2020;4(1):141–146.
   PubMedGoogle Scholar
• Dos Santos Ferreira L, Abreu LG, Calderipe CB, et al. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? a systematic review and meta-analysis. Osteoporos Int. 2021;32(12):2449–2459.
   PubMed Web of Science ®Google Scholar
• Anabtawi M, Tweedale H, Mahmood H. The role, efficacy and outcome measures for teriparatide use in the management of medication-related osteonecrosis of the jaw. Int J Oral Maxillofac Surg. 2021;50(4):501–510.
   PubMed Web of Science ®Google Scholar
• van de Laarschot DM, McKenna MJ, Abrahamsen B, et al. Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society. J Clin Endocrinol Metab. 2020;105(5):1682–1699.
   Web of Science ®Google Scholar
• Buerba RA, Sharma A, Ziino C, et al. Bisphosphonate and teriparatide use in thoracolumbar spinal fusion: a systematic review and meta-analysis of comparative studies. Spine (Phila Pa 1976). 2018;43(17):E1014–E23.
   PubMed Web of Science ®Google Scholar
• Fatima N, Massaad E, Hadzipasic M, et al. Assessment of the efficacy of teriparatide treatment for osteoporosis on lumbar fusion surgery outcomes: a systematic review and meta-analysis. Neurosurg Rev. 2021;44(3):1357–1370.
   PubMed Web of Science ®Google Scholar